Thanks or us this afternoon. joining
our turn call to the now Joining me to our to to review will quarter. development slide some Christine. website and update. will highlight the you third the Marcio the are have on today commercial Marcio provide Christine clinical accomplishments like on posted and financials. ask in we I'd
a platforms. integrated company start on to our spend to today's fully time Slide call biotech going build about I'm multiple path to has Let's talking continue that on X. leading,
medical rare new that and decades to a need. Our cancers. pipeline. orphan DMD From in year into be clinical mission we class a unmet effort, disorders earlier Day for suffering strong At the scientifically from this commercializes innovative patients potential therapy on been therapies in our discovers, development we our oncology developed company has development for high our rare from the and patients SMA base two Analyst this with two suffering over in develops business therapeutics went best last for detail
is then these solid best PTCXXX maximizes entered strategy efforts report am programs the generate the happy data recently path patients and revenue shareholder base. a commercial programs strong scientific development to the showing a early most in These determine returns. to have infrastructure that benefit and Our I clinical with clinic. have built to and PTCXXX advanced
continue build the orphan to stakeholders. to Over three next our our value all for and disease franchise growth five creating is to significant our strategy years of
As be you our position. excited X, chart to can in are such pipeline see we Slide on a unique on
a regulatory have therapies in as this and strong development, revenue portfolio therapy of We have base, approved. in a diverse gene includes and or review, candidates; talent molecules products as well been small strong
We the on will medical high maintain monogenetic rare disease space, focusing need. our focus on with unmet disorders
we Next X, executing report on to strategy. been I'm this on that have Slide already pleased
clinical robust therapy a with next stories we added with regulatory that therapy results one have of Agilis, acquisition the expected including With submitted three gene gene programs be is to company, year. program [ph]
puts to as principals rare one gene with time platforms spend ultra the development platform. happier In as with be reviewing the turn transforming CNS transaction. process, bring an position innovative will Slide America. first When platform to integration which to PTC I needed Latin treatments monogenetic from potential company This the two addition, in-licensed the was Agilis therapy using in of have call one newest public to want disorders. couldn’t this X. Please be to we is Akcea business we orphan life therapy in we I have began our you. commercializing disorders gene patients that our products of since the of to and the our closing that the treat
gene such interested We in to are therapy. approaches
focus Specifically effect. we utilizing therapy first low turnover wanted ensure to to gene with on targeting durability of tissues
that of their of being biotherapy. gene contained patients the therapy consider amounts small micro the of manufacturing to therapy through acquisition advantage has region We gene Agilis platform. a the of body use doses us led allowing lower delivering able also considerations These treat the to with to CNS
therapy FA Our opportunity and delivery to is are being What be targeted all common Decarboxylase seen for addition in or Aromatic each Acid AS. as Ataxia market Friedreich the exciting. three employed. AADC, these therapy Amino need programs or gene they have can that is therapies of of Angelman for in of disorders CNS in The gene medical deficiency high Syndrome unmet or gene
market programs Our these approximately combined is these combined global suffering this excess Including of Syndrome. indications market XX,XXX potential and the we billion. XXX,XXX We $X addressable estimate for deficiency the AADC patients, platform estimate is valuable XX,XXX FA that Angelman and for a X,XXX believe of from patients. in patients is patients
One major this of benefits therapy required. small the material is quantity CNS of the of approach
and requirement immunogenicity. direct therapy therapy the there the only only of allows small of This is of and Because is systemic into smaller particles. compared This risk brain For XX are the injection gene was a vector utilizes scalable CNS between reduced delivering is to for AADC approximately times contained two viral gene relatively modular lower viral [ph] manufacturing. XXXX instance, XX,XXX dose the dose doses total to dosing. tend to it the of used a micro dose be
therapy program. In fact AADC has almost been immune no response the observed in gene
the gene a for the of targeted that of in The cell this a be of to tissues. adds cells maintained to slowly is durability dividing required sum, In with is strong of issue therapy competitive the effective and the Lastly, low has allows growing dose gene combined another important therapy which lower targeting platform. an of advantage important because virus turnover tissue it CNS is rate response is the durability with point treatment.
orphan our area to forward neurological treat these of X, Slide to programs expertise. Turning key disorders therapy to the
years enabled commercial disorder experienced We patient rare depth the in our rare country and infrastructure products. for market over rare have the unmet two pricing, I'd We country and is now and advanced have by developing on XX disorder in in is our global commercializing discovering, the This high success genotyping to funding. more and medical pipeline. for market driving by basis medical effort understand programs and therapy with therapies experience commercializing and like of disorders most access our gene need. talk both
such atrophy devastating first, Let's and halts development spinal children infant turn deficiency with of sitting, up, this In motor X standing. milestones neurological most motor achieve similar holding to childhood as the X years starting are its with to disorder to in X. AADC head their a and is muscular age. AADC between disorder never results mortality deficiency or form Slide is severe
have functional, a to head Following hold developmental increases the have motor milestones, improvements and trials have to patients in walk. in five-year gene durable position, I in the clinical were The functions single these followup. including ability sit, clinical direct treatment, trial showed therapy even results shown and CNS to in stand, to that
substantial of is technique. benefit. program evidence into single the established Slide to Now let's dose The AADC using surgical turn treatment durable, has through [indiscernible] an clinical, long-term delivery delivered a gene direct via AADC XX. therapy
The first was eight treated ago. patient years
demonstrating Our the gene package followup regulatory in The of data over XX for has past using measured eight regulatory this years. motor package effect have relies The multiple these space. treated longest on data in patients improvements patients therapy term durability the from the scales. been
patients two here XX this. demonstrate clinical in Slide clinical trials. the seen at five-year improvements are Observed can in and you Developmental treated Motor followup. Scales improvement one see on The Peabody Here clinical
As was of share after these age seen initiated. history none patient remarkable experienced remarkable are natural therapy gross sitting patient. This in that robust treated gene transformative achieved. you cognitive like a Slide are observed demonstrated the an in this therapy I'd can development in motor On the video treatment I AADC ability in patient. of control, What's Patients changes head and see demonstrating gene improvement motor to therapy were treated AADC and XX, would in and such of from old both these see before durable including AADC and here videos important initial suffering a is of the years compelling. X one treatment. What standing. at milestones where share child every patient. fine skills motor deficiency studies gene about treatment you context when the rapid the improvement is regardless many their in will to When we have like of a
unable motor You treatment. age the to lift sit. has years child can or a is single head his At of received and he function X see limited
see, change. As one you substantial of was can followup there year after
growth we're of After improvement. and followup child upright independently You and grasping We sitting interacting therapy now function we The additional believe to impressive you see these results motor see rapidly age caregiver. child continued can years and the an are is X as of year at why bring to a and excited see fine as cognitive patients mirror. possible. and standing this the with can
submit on to We are expect BLA in now XXXX. and working the
frataxin FA gene Slide of and the is brain to repeat transition program. triple XX, turning micro for the to Now, the FA. in advanced a This most targeting of region protein, we'll gene is ataxia approximately utilizing loss the causing involved be the the disease directly in will again be in cause let me underlying therapy Ataxia Friedreich that is dosing. program therapy development
the by levels data see us The As that animal Slide dose proteins preclinical allows specious data the in we're patients. find in used encouraged robust showing have to an very appropriate above range you on be normal large been achieved. can XX, to
for this to We a high XX group the program FA Let's advocacy file patient leading will dosing plan patient advocacy relationship an from benefit and group. move start the Slide therapy believe We IND patients. to have We already good FA XX. engagement. gene FARA, program with in
move Let's slide XX. to
their very about for syndrome. in program are early forward We path including stage programs excited these Angelman the
creation This infrastructure Latin in programs. on to with brings to made and DMD the believe drive strong are therapy our have long will call now advances niche us gene commercial that pipeline franchise I the in value we pass review and for growing and and product oncology patients both our Marcio We America update our of near proud you the in-licensed to commercial terms new which opportunities. collaboration support I'll Marcio we which will Akcea our shareholders. also for two very leverages we substantial rights. new commercial ask
